TNF and inflammatory bowel disease: Factors accounting for such a discrepancy remain unknown but it is conceivable that differences in the presence of confounders (e.g. smoking, concomitant use of steroids, immunesuppressors, or TNF blockers) among the two IBD populations can account for the increased risk of URTI in the vedolizumab-treated UC patients.